Syra Madad, DHSc, MSc, MCP, CHEP

home / authors / syra-madad-dhsc-msc-mcp-chep

Chief Biopreparedness Officer at NYC Health + Hospitals.

Articles

Strategies for Improving Pandemic Preparedness

Strategies for Improving Pandemic Preparedness

Sophia Abene;Syra Madad, DHSc, MSc, MCP, CHEP
September 10th 2024

Syra Madad, DHSC, MSc, MCP, CHEP, outlines early surveillance systems and diagnostic innovations for enhancing pandemic management and response.

Read More

10 Key Pillars to an Effective Ebola Response

10 Key Pillars to an Effective Ebola Response

Syra Madad, DHSC, MSC; and Vikram Mukherjee, MD;Syra Madad, DHSc, MSc, MCP, CHEP
June 23rd 2021

EVD outbreaks this year serve as a reminder of the virus’ severity and the importance of having a containment strategy in place.

Read More

Latest Updated Articles

Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
Published: August 27th 2024 | Updated: August 28th 2024
Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
A Passion for Infectious Disease Education and Communication
Published: June 16th 2025 | Updated: June 24th 2025
A Passion for Infectious Disease Education and Communication
Geographic and Demographic Variations in Hepatitis C Mortality
Published: June 17th 2025 | Updated: June 24th 2025
Geographic and Demographic Variations in Hepatitis C Mortality
Psychiatric Symptoms Emerging Years After Infections Like Lyme and Tick-Borne Infections
Published: June 18th 2025 | Updated: June 24th 2025
Psychiatric Symptoms Emerging Years After Infections Like Lyme and Tick-Borne Infections
FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention
Published: June 18th 2025 | Updated: June 24th 2025
FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention
Dual-Targeting miRNAs Identified as Potential Therapeutics Against HCV and BVDV
Published: June 19th 2025 | Updated: June 24th 2025
Dual-Targeting miRNAs Identified as Potential Therapeutics Against HCV and BVDV
© 2025 MJH Life Sciences

All rights reserved.